CIBMTR Reporting Implementation Guide
0.1.8 - Trial Use 1
This page is part of the CIBMTR Reporting Implementation Guide (v0.1.8: Release Draft) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
{
"resourceType" : "MedicationAdministration",
"id" : "MedicationAdministration-Example2",
"meta" : {
"profile" : [
🔗 "http://fhir.nmdp.org/ig/cibmtr-reporting/StructureDefinition/cibmtr-medication-administration"
],
"security" : [
{
"system" : "http://terminology.cibmtr.org/codesystem/transplant-center",
"code" : "rc_99999",
"display" : "99999 My Transplant Center"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: MedicationAdministration MedicationAdministration-Example2</b></p><a name=\"MedicationAdministration-Example2\"> </a><a name=\"hcMedicationAdministration-Example2\"> </a><a name=\"MedicationAdministration-Example2-en-US\"> </a><p><b>status</b>: Completed</p><p><b>medication</b>: <span title=\"Codes:{http://www.nlm.nih.gov/research/umls/rxnorm 4179}, {http://www.nlm.nih.gov/research/umls/rxnorm 310248}, {http://www.nlm.nih.gov/research/umls/rxnorm 362972}, {http://www.nlm.nih.gov/research/umls/rxnorm 206832}\">ETOPOSIDE 20 MG/ML IV SOLN</span></p><p><b>subject</b>: <a href=\"Patient-PatientExample6.html\"> Female, DoB Unknown ( http://terminology.cibmtr.org/identifier/CRID#123456)</a></p><p><b>effective</b>: 2020-07-22 16:58:05+0000</p><p><b>reasonCode</b>: <span title=\"Codes:{http://snomed.info/sct 363346000}, {http://hl7.org/fhir/sid/icd-10-cm C80.1}\">Cancer (CMS/HCC)</span></p><p><b>request</b>: <a href=\"MedicationRequest-MedicationRequest-Etoposide-Example.html\">MedicationRequest: status = active; intent = order; medication[x] = ->etoposide (VEPESID) chemo IVPB; authoredOn = 2020-07-21 14:17:00+0000; reasonCode = Malignant neoplastic disease (disorder)</a></p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td><td><b>Method</b></td><td><b>Dose</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://snomed.info/sct 47625008}\">Intravenous route</span></td><td><span title=\"Codes:{http://snomed.info/sct 422145002}\">Inject - dosing instruction imperative (qualifier value)</span></td><td>73 milligram<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM codemg = 'mg')</span></td></tr></table></div>"
},
"status" : "completed",
"medicationCodeableConcept" : {
"coding" : [
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "4179",
"display" : "etoposide"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "310248",
"display" : "etoposide 20 MG/ML Injectable Solution"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "362972",
"display" : "etoposide Injectable Solution [Vepesid]"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "206832",
"display" : "etoposide 20 MG/ML Injectable Solution [Vepesid]"
}
],
"text" : "ETOPOSIDE 20 MG/ML IV SOLN"
},
"subject" : {
🔗 "reference" : "Patient/PatientExample6"
},
"effectiveDateTime" : "2020-07-22T16:58:05Z",
"reasonCode" : [
{
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "363346000",
"display" : "Malignant neoplastic disease (disorder)"
},
{
"system" : "http://hl7.org/fhir/sid/icd-10-cm",
"code" : "C80.1",
"display" : "Malignant (primary) neoplasm, unspecified"
}
],
"text" : "Cancer (CMS/HCC)"
}
],
"request" : {
🔗 "reference" : "MedicationRequest/MedicationRequest-Etoposide-Example"
},
"dosage" : {
"route" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "47625008",
"display" : "Intravenous route"
}
]
},
"method" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "422145002",
"display" : "Inject - dosing instruction imperative (qualifier value)"
}
]
},
"dose" : {
"value" : 73,
"unit" : "milligram",
"system" : "http://unitsofmeasure.org",
"code" : "mg"
}
}
}